Our Team

For decades, mental health treatment options have excluded the very promising segment of psychedelic-assisted therapies. Just as psychiatrists, psychologists, and other researchers were making incredible headway on their studies of compounds like MDMA, psilocybin, and Ayahuasca (among others) in the 1990’s, the U.S. government criminalized these substances, blocking research across the globe.

Efficacy rates for treating PTSD with MDMA-Assisted Therapy (MDMA-AT) exceed 87% in clinical trials. Despite this unprecedented therapeutic result, in August of 2024, the FDA determined not to approve MDMA-AT for the treatment of PTSD in the United States.

I am living proof that MDMA-Assisted Therapy (MDMA-AT) is safe, effective, life-changing, and even life-saving. By not approving MDMA-AT, the FDA is risking the lives of the 13 million Americans suffering from PTSD.

None of my previous therapies had ever come close to unravelling my trauma as MDMA-AT. At the June 2024 FDA Advisory Committee meeting, I posed the question: “How many more people need to die before we approve an effective therapy?” (Links to New York Times article.)

I am disappointed that the FDA has chosen to prevent millions of other Americans like myself, particularly survivors, from regaining resilience and improving the quality of life that was robbed from them. Instead, their lives will continue to be in jeopardy every single day.

The extraordinary promise of these therapeutic modalities cannot be overlooked, as the efficacy and impact of these treatments are setting a new bar for effective, safe, and enduring mental health treatments. Let’s accelerate the spread of traumatic recovery, grounded in science.

Please sign up to join our voice at Protea Foundation. Also, support organizations like MAPS.org, who continue to fund vital clinical research for the effective treatment of PTSD and related issues.